The coupling of hemoglobin sensing of physiological oxygen gradients to stimulation of nitric oxide (NO) bioactivity is an established principle of hypoxic blood flow. One mechanism proposed to explain this oxygen-sensing-NO bioactivity linkage postulates an essential role for the conserved Cys93 residue of the hemoglobin b-chain (bCys93) and, specifically, for S-nitrosation of bCys93 to form S-nitrosohemoglobin (SNO-Hb) 1 . The SNO-Hb hypothesis, which conceptually links hemoglobin and NO biology, has been debated intensely in recent years 2, 3 . This debate has precluded a consensus on physiological mechanisms and on assessment of the potential role of SNO-Hb in pathology. Here we describe new mouse models that exclusively express either human wild-type hemoglobin or human hemoglobin in which the bCys93 residue is replaced with alanine to assess the role of SNO-Hb in red blood cell-mediated hypoxic vasodilation. Substitution of this residue, precluding hemoglobin S-nitrosation, did not change total red blood cell S-nitrosothiol abundance but did shift S-nitrosothiol distribution to lower molecular weight species, consistent with the loss of SNO-Hb. Loss of bCys93 resulted in no deficits in systemic or pulmonary hemodynamics under basal conditions and, notably, did not affect isolated red blood celldependent hypoxic vasodilation. These results demonstrate that SNO-Hb is not essential for the physiologic coupling of erythrocyte deoxygenation with increased NO bioactivity in vivo.
The coupling of hemoglobin sensing of physiological oxygen gradients to stimulation of nitric oxide (NO) bioactivity is an established principle of hypoxic blood flow. One mechanism proposed to explain this oxygen-sensing-NO bioactivity linkage postulates an essential role for the conserved Cys93 residue of the hemoglobin b-chain (bCys93) and, specifically, for S-nitrosation of bCys93 to form S-nitrosohemoglobin (SNO-Hb) 1 . The SNO-Hb hypothesis, which conceptually links hemoglobin and NO biology, has been debated intensely in recent years 2, 3 . This debate has precluded a consensus on physiological mechanisms and on assessment of the potential role of SNO-Hb in pathology. Here we describe new mouse models that exclusively express either human wild-type hemoglobin or human hemoglobin in which the bCys93 residue is replaced with alanine to assess the role of SNO-Hb in red blood cell-mediated hypoxic vasodilation. Substitution of this residue, precluding hemoglobin S-nitrosation, did not change total red blood cell S-nitrosothiol abundance but did shift S-nitrosothiol distribution to lower molecular weight species, consistent with the loss of SNO-Hb. Loss of bCys93 resulted in no deficits in systemic or pulmonary hemodynamics under basal conditions and, notably, did not affect isolated red blood celldependent hypoxic vasodilation. These results demonstrate that SNO-Hb is not essential for the physiologic coupling of erythrocyte deoxygenation with increased NO bioactivity in vivo.
In addition to hemoglobin oxygen affinity, blood flow is a key component of the processes that match oxygen delivery to demand. Increased blood flow in response to hypoxia is an essential physiological response that does not correlate with dissolved oxygen tensions but does correlate with hemoglobin oxygen fractional saturation 4 . These observations have led to the concept that the red blood cell (RBC) itself is a regulator of flow and to the general paradigm that RBC and hemoglobin deoxygenation is coupled to the stimulation of vasodilation 1, 5, 6 . Three mechanisms for this coupling have been proposed (illustrated in Supplementary Fig. 1 online) and involve either ATP release and subsequent activation of endothelial nitric oxide synthase 7 , nitrite reduction to NO by deoxyhemoglobin 5 or SNO-Hb-dependent pathways 1 . In the last proposed mechanism, hemoglobin becomes S-nitros(yl)ated on a specific and conserved cysteine residue on the b-chain (bCys93) as RBCs become oxygenated in the lungs (forming SNO-Hb). In the R-state (relaxed state, high oxygen affinity hemoglobin conformation), SNO-Hb remains relatively unreactive, but, upon deoxygenation, T-state (tense state, low oxygen affinity hemoglobin conformation) SNO-Hb can rapidly react with thiols (glutathione or anion exchanger-1 thiols) and transmit a vasodilatory signal out of the RBC ( Supplementary Fig. 1 ) [8] [9] [10] [11] [12] . This hypothesis has been extended recently to suggest that dysfunction in this pathway leads to a variety of systemic vascular and pulmonary diseases and contributes to pathologic effects associated with diabetes, congestive heart failure and transfusion of banked blood [13] [14] [15] [16] [17] . These pioneering studies also have begun to resolve a long-standing question in hemoglobin biology, namely, the role of the highly conserved bCys93 residue. However, the function of SNO-Hb in vivo and its potential role in disease has been debated intensely over the past few years. Many aspects of the SNO-Hb hypothesis have been disputed, including the measurements of SNO-Hb concentrations and the mechanisms of SNO formation and bioactivity (Supplementary Fig. 1 ).
To directly address this issue and to explore the role of the conserved bCys93 residue, we created knock-in mouse models in which RBCs contained either wild-type (WT) human hemoglobin (HbC93) or human hemoglobin in which the bCys93 residue was replaced with alanine (HbC93A) ( Fig. 1a; Supplementary Fig. 2a ,b online shows the knock-in scheme). Sequencing of mouse genomic DNA (Fig. 1b) , isoelectric focusing of hemolysates (Fig. 1c) , b-globin protein sequencing by mass spectrometry (Fig. 1d,e) and a 5,5¢-dithio-bis(2-nitrobenzoic acid)-binding assay that showed a decrease of two reduced thiols per hemoglobin tetramer (Fig. 1f) indicate that bCys93 was changed to alanine. No change in total glutathione abundance (Fig. 1g) was observed, suggesting no compensatory upregulation of the other major thiol pool in RBCs. Finally, replacement of bCys93 with alanine resulted in a modest, but significant, increase in RBC oxygen affinity (Fig. 1h) , which is consistent with cell-free recombinant hemoglobin studies 18 .
Hematological indices and urine concentrations were measured in HbC93 and HbC93A mice. Small increases in hemoglobin abundance, red blood cell distribution widths, mean corpuscular volumes and mean corpuscular hemoglobin were observed in HbC93A compared to HbC93 mice; however, these values were in the normal range (Supplementary Supplementary Figs. 2,3 online) ). Finally, embryonic development ( Supplementary Fig. 2 ) and the size of litters derived from each group (data not shown) were not substantially different. These results suggest that the HbC93A mice develop normally.
To evaluate the role of bCys93 S-nitrosation in RBC-dependent modulation of NO-bioactivity, we first characterized basal nitric oxide metabolism in the circulation by measuring the abundance of NO metabolites, including nitrate, nitrite, S-nitrosothiols and C-or N-nitroso compounds (referred to as XNO), in the plasma and RBCs. Total NO production (Fig. 2) in HbC93A and HbC93 mice were similar (nitrate levels were not different; 33.6 ± 10.6 mM in HbC93 mice and 29.5 ± 1.2 mM in HbC93A mice, n ¼ 3 per group). Notably, no differences in circulating NO metabolite abundance were observed except in the case of plasma nitrite abundance, which was lower in HbC93A mice (Fig. 2a) . A trend toward lower whole-blood nitrite levels was also observed in HbC93A mice (Fig. 2d) . Nitrite concentration was not associated with differing levels of endothelial nitric oxide synthase (eNOS) expression or activity ( Supplementary  Fig. 4 online). Recent studies show that loss of the bCys93 residue increases the nitrite reductase activity of deoxyhemoglobin 19, 20 , a result that we also observed with HbC93A RBCs (data not shown), suggesting that this activity may account for the observed lower steady-state nitrite levels. Collectively, these data suggest that loss of bCys93 does not result in adaptive increases in endogenous NO formation. S-nitrosothiol abundance in RBCs was not significantly different between HbC93A and HbC93 mice ( Fig. 2e ; 214.6 ± 37 nM and 147.9 ± 28.6 nM for HbC93A and HbC93 mice, respectively (n ¼ 6 mice) in packed red blood cells). Of note, however, the distribution of S-nitrosothiols was altered. In HbC93 RBCs, 78.2% ± 14.3% of the SNOs were in the high molecular weight fraction, which is consistent with localization predominantly on hemoglobin. In the HbC93A RBCs, however, high molecular weight SNOs were undetectable (Fig. 2e) . More than 99% of SNOs were in the low molecular weight fraction, most likely as S-nitrosoglutathione, underscoring a dynamic transnitrosation equilibrium between SNO-Hb and low molecular weight thiols (as previously indicated 8, 21 ), which, in the absence of bCys93, is shifted toward S-nitrosoglutathione. This conclusion is further supported by the absence of any effect of bCys93 substitution on XNO distribution in RBCs (Fig. 2f) . In summary, our results show no functionally noteworthy phenotypic or biochemical differences between HbC93 and HbC93A mice, except for a relatively small (B20%) decrease in circulating nitrite levels and a redistribution of RBC SNOs from bCys93 in hemoglobin to a nonhemoglobin fraction.
To evaluate the potential hemodynamic effects of the altered RBC SNO profile, we measured mean arterial pressure ( Fig. 3a and Supplementary Fig. 5a online), systolic pressure ( Supplementary  Fig. 5b ), diastolic pressure ( Supplementary Fig. 5c ) and heart rate ( Supplementary Fig. 5d ). We observed no differences between HbC93 and HbC93A mice, suggesting that SNO-Hb is not essential for physiologic modulation of blood pressure.
Recent studies suggest that depletion of SNO-Hb leads to pulmonary hypertension 16 . However, no differences in right ventricular pressures between HbC93 and HbC93A mice were observed (Fig. 3b) . Moreover, assessment of right ventricular hypertrophy (Fig. 3c) and pulmonary arterial wall thickness (Fig. 3d) , which are diagnostic features for pulmonary hypertension, showed no differences. Collectively, these data indicate that loss of bCys93 and the associated loss of SNO-Hb does not adversely affect systemic or pulmonary hemodynamics. These data do not rule out a role for other RBC SNOs 22 , but they do indicate that allosteric regulation of SNO-Hb bioactivity is not an essential component of the physiologic mechanisms that control pulmonary blood flow.
Given the multiple studies documenting a crucial role for SNO-Hb in hypoxic blood vasodilation, we were surprised by the lack of a phenotype in bCys93-deficient mice under physiological conditions. Because hypoxia is an essential element in the SNO-Hb hypothesis, we first considered that a role for this residue may only be evident under conditions of hypoxic stress. To test this, we exposed HbC93 and HbC93A mice to two types of exercise stress that model acute (analogous to sprinting) and chronic (analogous to long-distance running) exercise resulting in varying degrees of hypoxic stress.
HbC93 and HbC93A mice performed equally well at both exercise regimes (Fig. 4a,b) , suggesting that SNO-Hb is not essential for global exercise capacity. We hypothesized that adaptive responses of the vasculature, such as differences in capillary densities, could compensate in the absence of SNO-Hb; however, no changes in capillary density in the heart were observed ( Supplementary Fig. 6 online) .
Finally, because multiple mechanisms contribute to regulation of hypoxic blood flow in vivo, which could be upregulated to compensate for loss of SNO-Hb bioactivity, we tested the ability of isolated RBCs to stimulate hypoxic vasodilation responses in rabbit pulmonary arteries in vessel bioassay experiments. Previous studies have shown that addition of RBCs under oxygenated (21% oxygen) conditions constricts vessels (consistent with scavenging of endogenous NO), whereas RBC addition to vessels pre-equilibrated at r1% oxygen (tensions that result in RBC deoxygenation) elicits a transient vasodilation response that is followed by vasoconstriction 11 . These data were pivotal in the generation of the SNO-Hb hypothesis. Addition of RBCs from HbC93 mice to the rabbit arteries reproduced these data, causing vasoconstriction at 21% oxygen and a transient vasodilation followed by vasoconstriction at 0% oxygen (Fig. 4c) . Similar effects were observed with HbC93A RBCs (Fig. 4d) identical (Fig. 4e) , indicating that bCys93, and hence SNO-Hb, are not required for RBC-dependent hypoxic vasodilation. We have previously reported that under nitrite-free conditions, this dilation response, which has been ascribed to RBC SNO-Hb, is most likely due to ATP release from hypoxic RBCs 19 . According to this model, ATP is released from hypoxic RBCs, binds endothelial purinergic receptors and thereby stimulates NO production by eNOS, resulting in vasodilation 7 . Consistent with ATP release as the mediator of the vasodilation induced by HbC93 and HbC93A RBCs, hypoxic vasodilation was inhibited by 490% in the presence of the eNOS inhibitor LNMMA (NG-monomethyl L-arginine, 1 mM) (Fig. 4f) . It should be pointed out that hypoxic vasodilation responses ascribed to SNO-Hb have also been stated to occur with denuded vessels 15, 23 . Denudation removes the endothelium, and hence eNOS, conceivably precluding ATPdependent pathways. However, both HbC93 and HbC93A RBCs dilated denuded vessels to similar extents at low oxygen tensions ( Supplementary Fig. 7 online) . Moreover, ATP also dilated denuded vessels (Supplementary Figure 7) . This response is most likely due to metabolism of ATP to adenosine, an endothelium-independent vasodilator. A role for adenosine is indicated by significant (P o 0.03) inhibition of hypoxic RBC-dependent dilation of denuded vessels by the adenosine receptor antagonist theophylline; this inhibition was equivalent with RBCs from HbC93 mice and from HbC93A mice ( Supplementary Fig. 7 ). We present this data to show that dilation of denuded vessels by hypoxic RBCs does not directly exclude ATPdependent effects and that SNO-Hb is not required for vasodilation in this assay, as well as to underscore the potential for SNO-Hbindependent mechanisms for RBC-induced vasodilation. Further studies are required to determine how ATP released from hypoxic RBCs can be metabolized to adenosine and then mediate dilation of denuded vessels. In summary, our data demonstrate that bCys93 is not essential for normal development or physiology under basal or exercise-stress conditions, that the absence of SNO-Hb does not result in pulmonary hypertension under normal conditions and that SNO-Hb is not required for RBCs to stimulate hypoxic vasodilation ex vivo. Although it is possible that the use of a humanized mouse model may mask a physiological effect of bCys93 deletion, our studies strongly suggest that SNO-Hb does not play an essential part as a physiological regulator. We hypothesize that the conserved bCys93 residue has a functional role in diseases characterized by vascular oxidative or nitrosative stress [24] [25] [26] . The use of HbC93 and HbC93A mouse models should provide key insights into the role of bCys93 and SNO-Hb in these disorders.
METHODS
Production of knock-in mice. We performed the replacement of the genes encoding mouse a-and b-globin with the genes encoding human a-and b-globin essentially as previously described 27 . See Supplementary Figure 2 for the knock-in scheme. We performed all studies with mice according to institutionally (University of Alabama at Birmingham Institutional Animal Care and Use Committee) approved protocols.
Red blood cell thiol measurements. We measured total RBC glutathione and hemoglobin and surface-accessible reduced thiol as described in the Supplementary Methods online.
Hematology. We determined hematology profiles as previously described 27 .
RBC-hemoglobin oxygen affinity. We determined hemoglobin oxygen affinity in intact RBCs as previously described 19 .
Hemodynamics. We measured hemodynamic parameters noninvasively with a specialized differential pressure transducer tail cuff (Kent Scientific). We determined right ventricular pressures and measured Fulton index to assess pulmonary hypertension as previously described 28 .
Vessel bioassays. We performed vessel studies with female rabbit pulmonary arteries preconstricted with phenylephrine in Krebs Heinseleit buffer as previously described 19 . We collected whole blood from either HbC93 or HbC93A mice by cardiac puncture and washed the RBC pellet once with air-equilibrated PBS (2,000g, 90 s, 22 1C). We then immediately added a 0. either 21% or 0% oxygen. We determined vasodilatory effects by measuring the change in tension and expressing this as a percentage relaxation with respect to the maximal phenylephrine constriction. We performed vessel bioassay experiments in decreased lighting to protect photo-labile S-nitrosothiols.
Measurement of nitric oxide metabolites. We measured the abundance of NO metabolites as previously described 29 . For RBC measurements, we also passed samples through a Sephadex G-25 gel-filtration column (pre-equilibrated with PBS and 10 mM dietheylene triamine penta-acetic acid (DTPA, Sigma) to assess S-nitrosothiol and XNO distribution between high molecular weight (410 kDa, hemoglobin-containing) and low molecular weight (o10 kDa) fractions.
Exercise stress tests. We exposed male mice to either graded or endurance exercise tests on a treadmill (Exer6M, Columbus Instruments) and, in each case, recorded time to fatigue, that is, the time at which mice could no longer maintain a running pace despite external stimuli.
Liquid chromatography-tandem mass spectometry of globin polypeptides. See Supplementary Methods for details.
Capillary density determination. We determined capillary density in the heart as previously described 30 .
Statistical analyses. All results are reported as the mean ± s.e.m. We performed statistical analysis with GraphPad Prism 4 software. We assessed differences between the groups by Student's unpaired t-test. Dose-dependent (acetycholine or ATP, Supplementary Figs. 4 and 7 ) vasodilation experiments were compared by two-way ANOVA analysis.
